-
GenScript Biotech Expands in Australia with New Sydney Operations and Logistics Center
•
GenScript Biotech Corporation (HKG: 1548), a leading Chinese biotechnology company, has announced the establishment of a new operations site and logistics center in Sydney, Australia. This strategic move highlights GenScript’s commitment to supporting the burgeoning biotechnology sector in Australia. Sydney Facility’s Role in Streamlining OperationsThe new Sydney facility is designed…
-
GenScript Dissolves Merger with CAR-T Specialist Legend Biotech, Reclassifies as Associated Company
•
GenScript Biotech Corporation (HKG: 1548), a comprehensive life science research and application service and product provider based in China, has announced the dissolution of its merger with Legend Biotech Corporation (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T-cell therapy. The decision to dissolve the merger was influenced by…
-
Legend Biotech CEO Addresses Biosecure Act Concerns Amid Q2 2024 Earnings Report
•
Legend Biotech Corporation (Nasdaq: LEGN), a leading Chinese biopharmaceutical company, has released its financial results for the second quarter of 2024. Amidst recent speculation about potential implications from the U.S. Biosecure Act, CEO Ying Huang addressed concerns during the earnings call. The U.S. House of Representatives’ committee on China had…
-
GenScript Biotech Receives Over USD 410 Million in Milestone Payments for CAR-T Therapy from Janssen Biotech
•
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced that it has received a total of USD 410 million in milestone payments from Janssen Biotech, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ). These payments are part of a licensing agreement with its…
-
GenScript Shares Slide on US Congressional Request for FBI Investigation
•
Shares of GenScript Biotechnology Co., Ltd (HKG: 1548), a China-based Contract Development and Manufacturing Organization (CDMO), plummeted over 17% in trading today following a request by a US House of Representatives committee on China for the FBI to investigate the company and its subsidiaries. The committee, led by chair John…
-
GenScript’s Subsidiary Legend Biotech Expands EU Approval for CAR-T Therapy Carvykti
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), has secured an expanded indication approval from the European Union for its BCMA-targeted chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel). The therapy is now approved as a…
-
GenScript Biotech Corporation Reports 34.2% YOY Revenue Growth in 2023 Financial Results
•
China-based GenScript Biotech Corporation (HKG: 1548) has announced its financial results for 2023, reporting revenues of USD 839.5 million for the year, marking a 34.2% year-on-year (YOY) increase. External revenues from non-cell therapy business reached USD 554.5 million, up 8.9% YOY, while cell therapy sales soared to USD 285 million,…
-
Carvykti CAR-T Therapy Sales Reach $157 Million in Q1 2024, Reports GenScript Subsidiary Legend Biotech
•
GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO) based in China, has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), achieved sales of USD 157 million for its BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), in the first quarter of 2024, which…
-
Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use
•
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced that its subsidiary Legend Biotech Corporation’s (NASDAQ: LEGN) BCMA-targeted chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), has received a recommendation from the US FDA’s Oncologic Drugs Advisory Committee (ODAC). Following a review…
-
Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use
•
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced that its subsidiary Legend Biotech Corporation’s (NASDAQ: LEGN) BCMA-targeted chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), has received a recommendation from the US FDA’s Oncologic Drugs Advisory Committee (ODAC). Following a review…
-
GenScript’s Subsidiary Legend Biotech Gets CHMP Nod for Carvykti Label Expansion in Multiple Myeloma
•
GenScript Biotech Corporation (HKG: 1548), a China-based Contract Research Organization (CRO), has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the label expansion of its (BCMA)-directed chimeric antigen receptor T…
-
Legend Biotech’s Carvykti Files for European Approval as Second-Line MM Treatment
•
GenScipt Biotech Corp. (HKG: 1548), a China-based Contract Development and Manufacturing Organization (CDMO), through its subsidiary Legend Biotech Corporation (NASDAQ: LEGN), has announced a market approval filing in Europe for its chimeric antigen receptor (CAR)-T therapy Carvykti (ciltacabtagene autoleucel). The therapy is proposed as a second-line treatment for recurrent/refractory (R/R)…
-
GenScipt Subsidiary Legend Biotech Finalizes Licensing Deal with Novartis for DLL3 CAR-T Therapies
•
GenScipt Biotech Corp., a China-based Contract Development and Manufacturing Organization (CDMO) (HKG: 1548), has announced that the closing conditions for a licensing agreement between its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), and the Swiss pharmaceutical giant Novartis AG (NYSE: NVS) have been met. The agreement, initially revealed in November 2023,…
-
Legend Biotech’s Carvykti Therapy to Include Myeloid Neoplasms Warning in Label Update
•
GenScript Biotech Corporation (HKG: 1548), a China-based Contract Research Organization (CRO), has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), will update the warning label for its BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), to account for the potential risk of myeloid neoplasms in patients…
-
GenScript Reports $152 Million in Sales for Carvykti as of September 30, 2023
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), achieved sales of USD 152 million for its BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), as of September 30, 2023. This represents a year-on-year growth rate…
